Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5547 - Analysis of immunosuppressive factors produced by tumorspheres in NSCLC. Prognostic value of Galectin-3 in adenocarcinoma

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Susana Torres Martinez

Citation

Annals of Oncology (2019) 30 (suppl_5): v585-v590. 10.1093/annonc/mdz258

Authors

S. Torres Martinez1, A. Herreros Pomares2, F. Zhang1, S. Calabuig-Fariñas3, Á. González1, R. Sirera4, A. Moreno-Manuel1, M. Mosqueda2, E. Escorihuela2, E. Duréndez2, S. Gallach2, J. Garde5, R. Guijarro6, E. Jantus-Lewintre7, C. Camps8

Author affiliations

  • 1 Molecular Oncology Laboratory, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 2 Molecular Oncology Laboratory-ciberonc, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 3 Department Of Pathology, Universitat De València, Molecular Oncology Laboratory-CIBERONC, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 4 Department Of Biotechnology, Universidad Politécnica De Valencia, CIBERONC, Valencia/ES
  • 5 Department Of Medical Oncology, Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 6 Ciberonc, Department of Thoracic Surgery, Hospital General Universitario de Valencia, Department of Surgery, Universitat de València, Valencia/ES
  • 7 Department Of Biotechnology, Universidad Politécnica De Valencia, Molecular Oncology Laboratory-CIBERONC, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 8 Department Of Medical Oncology, Hospital General Universitario De Valencia; Department Of Medicine, Hospital General Universitario De Valencia, Fundación de Investigación Hospital General Universitario de Valencia, Molecular Oncology Laboratory-CIBERONC, 46014 - Valencia/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5547

Background

Cancer stem cells (CSCs) are targets poorly recognized by the immune surveillance system given that they induce an immunosuppressive microenvironment. The aim of this work is to study the interactions between CSCs and the immune microenvironment in NSCLC.

Methods

Tumor cells from 8 resected NSCLC patients and 12 cell lines were established as tumorspheres enriched in CSCs and as monolayers. The gene expression of IL-4, IL-10, IL6, IL8 and LGALS-3 was analyzed by RTqPCR. Results were validated at a protein level by a sensitivity bead-based multiplex immunoassay using the Millipore kit for Luminex 100/200. The prognostic value of these factors in silico was determined in a cohort of 661 patients from The Cancer Genome Atlas (TCGA). Prognostic value was assessed by Cox regression and Kaplan‐Meier curves (long rank‐test).

Results

Patients’ median age was 67 years [57-74], 62% were male, and 62.5% were adenocarcinomas (ADC). Gene expression analysis revealed that LGALS3 was significantly higher expressed in lung tumorspheres. By contrast, adherent cells had significantly higher expression of IL6. In accordance with gene expression levels, we observed significant differences in the secretion of these two soluble factors (IL-6 and Galectin-3) between adherent cells and tumorspheres. No significant results were observed for IL-8, IL-10 and IL-4 expression and secretion. Survival analysis showed that ADC patients with higher LGALS3 expression decreased overall survival (OS, 40.49 vs. 87.90 months, p = 0.005) and relapse-free survival (RFS, 25.28 vs. 41.25 months, p = 0.003) than the group with LGALS3 expression below the median. The multivariate analysis reported that LGALS3 expression can be established as an independent prognostic biomarker for OS [HR = 1.75; 95% CI, 1.19-2.59; p = 0.004] and for PFS in lung adenocarcinoma [HR = 1.68; 95% CI, 1.22-2.32; p = 0.001].

Conclusions

The secretion of Galectin-3 by Lung CSCs may be involved in the modulation of the immune microenvironment. Galectin-3 is an independent prognostic biomarker for overall survival and relapse-free survival in lung adenocarcinomas. Supported by grants CB16/12/00350, PI18/00266 and PI15-00753 from ISCIII and ACIF/2018/275 from GVA and FSE.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fundación Hospital General Universitario de Valencia.

Funding

CB16/12/00350, PI18/00266 and PI15-00753 from ISCIII and ACIF/2018/275 from GVA and FSE.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.